Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma

Respiration

Volumn 67, Issue 1, 2000, Pages 36-40

  König, Jens Ekkehard ^c   Tolnay, Edina ^a   Wiethege, Thorsten ^b   Müller, Klaus Michael ^c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c NONE

Author keywords

Diffuse malignant mesothelioma; flt 1 receptor; Histological differentiation; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MACROPHAGE; MAJOR CLINICAL STUDY; MICROVASCULATURE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR DIFFERENTIATION;

EID: 0342948906     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029460     Document Type: Article

References (25)

1. Folkman J: Tumor angiogenesis; in Mendelson J (ed): The Molecular Basis of Cancer. Philadelphia, Saunders, 1995, pp 207-232.
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
3. Brown LF, Berse B, Jackman RF, Tognazzi K, Manseau E, Dvorak H, Senger DR: Increased expression of VPF and its receptors in kidney and bladder carcinoma. Am J Pathol 1993;143: 1255-1262.
4. Brown LF, Berse B, Jackman RF, Tognazzi K, Manseau E, Dvorak H, Senger DR: Expression of vascular permeability factor (VEGF) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
5. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Janice A, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (VEGF) in tumors: Concentration in tumor blood vessels. J Exp Med 1991;174:1275-1278.
6. Kendall R, Wang G, Thomas A: Identification of a natural soluble form of VEGF receptor, fIt-I and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226: 324-328.
7. Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J, Van Mark E: Syndecan-1 expression in malignant mesothelioma - Correlation with cell differentiation. WT1 expression and clinical outcome. J Pathol 1998;186: 300-305.
8. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
9. Shweiki D, Itin A, Neufeld G: Patterns of expression of VEGF and receptors in mice suggest a role in hormonally regulated angiogenesis. Clin Invest 1993;91:2235-2236.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
11. Tolnay E, Wiethege Th, Kuhnen C, Wulf M, Voss B, Müller K-M: Expression of type IV collagenasc correlates with the expression of VEGF in primary non-small cell lung cancer. J Cancer Res Clin Oncol 1997;123:652-658.
12. Tolnay E, Wiethege Th, Szondy K, Appel J, Kuhnen C, Müller K-M: Expression des vaskulären endothelialen Wachstumsfaktors (VEGF), TNM Status and Überlebenszeit bei nicht-kleinzelligen Karzinomen der Lunge (NSCLC). Pneumologie 1997;51:245.
13. Tolnay E, Kuhnen C, Voss B, Wiethege Th, Müller K-M: Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 1998;432:61-65.
14. Tolnay E, Kuhnen C, König JE, Voss B, Müller K-M: Hepatocyte growth factor/scatter factor and its receptor cMet are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998;124:291-296.
15. Ferrara N, Houck K, Jakema L: Molecular and biological properties of the vascular endothelial growth factor family of proteins. J Endocrinol 1992;13:18-32.
16. Goto F, Weindel K: Synergistic effects of VEGF on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993;9:508-514.
17. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Stern D, Familletti PC, Pan Y-CE, Olander JV, Conolly DT: VPF - A tumor derived polypcptidc that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-1541.
18. König J, Tolnay E, Wiethege T, Müller K-M: Expression of vascular endothelial growth factor (VEGF) in diffuse malignant pleural mesothelioma. Virchows Arch 1999;435:8-12.
19. Jones JSP: The formation and function of the mesothelioma panel of the commission of the European Community. Office for Official Publications of the European Communities, Health and Safety Series, Luxembourg 1993; EUR 14522.
20. WHO: International Histological Classification of Tumours; No. 1, Histological Typing of Lung Tumours, ed 3. Geneva, WHO, 1999.
21. Cordell JL, Fallini B, Erber WN: Immunoenzymatic labeling of monoclonal antibodies using immunocomplexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem 1984;32:219-229.
22. Wiethege Th, Voss B, Pohle T, Fisseler-Eckhoff A, Müller K-M: Localization of clastase and tumor necrosis factor alpha mRNA by non-radioactive in situ hybridization in cultures of alveolar macrophages. Pathol Res Pract 1991; 187:912-915.
23. Jones JSP, Brachet EA, Butler EB: The pleura and its pathology; in Jones JSP (ed): Pathology of the Mesothelium. London, Springer, 1987, pp 1-128.
24. Antony V, Hott J, Godbey W, Holm K: Angiogenesis in mesotheliomas - Role of mesothelial cell derived IL-8. Chest 1996;109:21S-22S.
25. Barinaga M: Designing therapies that target tumor blood vessels. Science 1997;175:282-284.